메뉴 건너뛰기




Volumn 85, Issue 21, 2011, Pages 10945-10954

H5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans

Author keywords

[No Author keywords available]

Indexed keywords

H5N1 VIRUS LIKE PARTICLE VACCINE; HEMAGGLUTININ 1; HEMAGGLUTININ 1 RECEPTOR; HEMAGGLUTININ 2; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MATRIX 1 PROTEIN; MATRIX PROTEIN; NEUTRALIZING ANTIBODY; PLACEBO; SIALIC ACID; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS SIALIDASE;

EID: 80055113889     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05406-11     Document Type: Article
Times cited : (89)

References (52)
  • 1
    • 69149086060 scopus 로고    scopus 로고
    • Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine
    • Beigel, J. H., J. Voell, C. Y. Huang, P. D. Burbelo, and H. C. Lane. 2009. Safety and immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J. Infect. Dis. 200:501-509.
    • (2009) J. Infect. Dis. , vol.200 , pp. 501-509
    • Beigel, J.H.1    Voell, J.2    Huang, C.Y.3    Burbelo, P.D.4    Lane, H.C.5
  • 2
    • 40549088240 scopus 로고    scopus 로고
    • Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults
    • Bernstein, D. I., et al. 2008. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J. Infect. Dis. 197: 667-675.
    • (2008) J. Infect. Dis. , vol.197 , pp. 667-675
    • Bernstein, D.I.1
  • 3
    • 77956837160 scopus 로고    scopus 로고
    • Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets
    • Bosch, B. J., et al. 2010. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 84:10366-10374.
    • (2010) J. Virol. , vol.84 , pp. 10366-10374
    • Bosch, B.J.1
  • 4
    • 42949157327 scopus 로고    scopus 로고
    • Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle
    • Bright, R. A., et al. 2008. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 3:e1501.
    • (2008) PLoS One , vol.3
    • Bright, R.A.1
  • 5
    • 34247139232 scopus 로고    scopus 로고
    • Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin
    • Bright, R. A., et al. 2007. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25:3871-3878.
    • (2007) Vaccine , vol.25 , pp. 3871-3878
    • Bright, R.A.1
  • 6
    • 79952468781 scopus 로고    scopus 로고
    • The humoral response to Gardasil(R) over four years as defined by Total IgG and competitive Luminex immunoassay
    • Brown, D. R., et al. 2011. The humoral response to Gardasil(R) over four years as defined by Total IgG and competitive Luminex immunoassay. Hum. Vaccin. 7:230-238.
    • (2011) Hum. Vaccin. , vol.7 , pp. 230-238
    • Brown, D.R.1
  • 7
    • 0026662909 scopus 로고
    • Structural basis of antigenic variation: studies of influenza virus neuraminidase
    • Colman, P. M. 1992. Structural basis of antigenic variation: studies of influenza virus neuraminidase. Immunol. Cell Biol. 70:209-214.
    • (1992) Immunol. Cell Biol. , vol.70 , pp. 209-214
    • Colman, P.M.1
  • 8
    • 0033522494 scopus 로고    scopus 로고
    • Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes
    • Crawford, J., et al. 1999. Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. Vaccine 17:2265-2274.
    • (1999) Vaccine , vol.17 , pp. 2265-2274
    • Crawford, J.1
  • 9
    • 77953710988 scopus 로고    scopus 로고
    • Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine
    • Deschuyteneer, M., et al. 2010. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum. Vaccin. 6:407-419.
    • (2010) Hum. Vaccin. , vol.6 , pp. 407-419
    • Deschuyteneer, M.1
  • 10
    • 47849101644 scopus 로고    scopus 로고
    • FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007
    • Eichelberger, M., et al. 2008. FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine 26:4299-4303.
    • (2008) Vaccine , vol.26 , pp. 4299-4303
    • Eichelberger, M.1
  • 11
    • 53649110260 scopus 로고    scopus 로고
    • Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay
    • Eichelberger, M. C., A. Hassantoufighi, M. Wu, and M. Li. 2008. Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. Virol. J. 5:109.
    • (2008) Virol. J. , vol.5 , pp. 109
    • Eichelberger, M.C.1    Hassantoufighi, A.2    Wu, M.3    Li, M.4
  • 13
    • 79954594723 scopus 로고    scopus 로고
    • Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay
    • Gavrilov, V., et al. 2011. Influenza virus-like particles as a new tool for vaccine immunogenicity testing: validation of a neuraminidase neutralizing antibody assay. J. Virol. Methods 173:364-373.
    • (2011) J. Virol. Methods , vol.173 , pp. 364-373
    • Gavrilov, V.1
  • 14
    • 0032735685 scopus 로고    scopus 로고
    • Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts
    • Katz, J. M., et al. 1999. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J. Infect. Dis. 180:1763-1770.
    • (1999) J. Infect. Dis. , vol.180 , pp. 1763-1770
    • Katz, J.M.1
  • 15
    • 79951812752 scopus 로고    scopus 로고
    • HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection
    • Kemp, T. J., et al. 2011. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 29:2011-2014.
    • (2011) Vaccine , vol.29 , pp. 2011-2014
    • Kemp, T.J.1
  • 16
    • 77953009742 scopus 로고    scopus 로고
    • Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus
    • Khurana, S., et al. 2010. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci. Transl. Med. 2:15ra5.
    • (2010) Sci. Transl. Med. , vol.2
    • Khurana, S.1
  • 17
    • 79960563634 scopus 로고    scopus 로고
    • Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines
    • Khurana, S., et al. 2011. Recombinant HA1 produced in E. coli forms functional oligomers and generates strain-specific SRID potency antibodies for pandemic influenza vaccines. Vaccine 29:5657-5665.
    • (2011) Vaccine , vol.29 , pp. 5657-5665
    • Khurana, S.1
  • 18
    • 66149149791 scopus 로고    scopus 로고
    • Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets
    • Khurana, S., et al. 2009. Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med. 6:e1000049.
    • (2009) PLoS Med , vol.6
    • Khurana, S.1
  • 19
    • 79957840765 scopus 로고    scopus 로고
    • MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines
    • Khurana, S., et al. 2011. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3:85ra48.
    • (2011) Sci. Transl. Med. , vol.3
    • Khurana, S.1
  • 20
    • 78651396311 scopus 로고    scopus 로고
    • Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and crossprotective immunity in ferrets
    • Khurana, S., et al. 2011. Bacterial HA1 vaccine against pandemic H5N1 influenza virus: evidence of oligomerization, hemagglutination, and crossprotective immunity in ferrets. J. Virol. 85:1246-1256.
    • (2011) J. Virol. , vol.85 , pp. 1246-1256
    • Khurana, S.1
  • 21
    • 77955411860 scopus 로고    scopus 로고
    • Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus
    • Khurana, S., et al. 2010. Properly folded bacterially expressed H1N1 hemagglutinin globular head and ectodomain vaccines protect ferrets against H1N1 pandemic influenza virus. PLoS One 5:e11548.
    • (2010) PLoS One , vol.5
    • Khurana, S.1
  • 22
    • 0029837041 scopus 로고    scopus 로고
    • Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults
    • Lakey, D. L., et al. 1996. Recombinant baculovirus influenza A hemagglutinin vaccines are well tolerated and immunogenic in healthy adults. J. Infect. Dis. 174:838-841.
    • (1996) J. Infect. Dis. , vol.174 , pp. 838-841
    • Lakey, D.L.1
  • 23
    • 78650981716 scopus 로고    scopus 로고
    • Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza
    • Landry, N., et al. 2010. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 5:e15559.
    • (2010) PLoS One , vol.5
    • Landry, N.1
  • 24
    • 77951883155 scopus 로고    scopus 로고
    • Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults
    • Langley, J. M., et al. 2010. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J. Infect. Dis. 201:1644-1653.
    • (2010) J. Infect. Dis. , vol.201 , pp. 1644-1653
    • Langley, J.M.1
  • 25
    • 0034972583 scopus 로고    scopus 로고
    • Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins
    • Latham, T., and J. M. Galarza. 2001. Formation of wild-type and chimeric influenza virus-like particles following simultaneous expression of only four structural proteins. J. Virol. 75:6154-6165.
    • (2001) J. Virol. , vol.75 , pp. 6154-6165
    • Latham, T.1    Galarza, J.M.2
  • 26
    • 33646349451 scopus 로고    scopus 로고
    • Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection
    • Li, X., et al. 2006. Essential sequence of influenza neuraminidase DNA to provide protection against lethal viral infection. DNA Cell Biol. 25:197-205.
    • (2006) DNA Cell Biol , vol.25 , pp. 197-205
    • Li, X.1
  • 27
    • 80053606312 scopus 로고    scopus 로고
    • Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico
    • 2 August doi: 10.1016/j.vaccine.2001.07.099
    • Lopez-Macias, C., et al. 2 August 2011. Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico. Vaccine. doi: 10.1016/j.vaccine.2001.07.099.
    • (2011) Vaccine
    • Lopez-Macias, C.1
  • 28
    • 79952228974 scopus 로고    scopus 로고
    • A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells
    • Lu, H., et al. 2011. A rapid Flp-In system for expression of secreted H5N1 influenza hemagglutinin vaccine immunogen in mammalian cells. PLoS One 6:e17297.
    • (2011) PLoS One , vol.6
    • Lu, H.1
  • 29
    • 0025370971 scopus 로고
    • Rotavirus proteins VP7, NS28, and VP4 form oligomeric structures
    • Maass, D. R., and P. H. Atkinson. 1990. Rotavirus proteins VP7, NS28, and VP4 form oligomeric structures. J. Virol. 64:2632-2641.
    • (1990) J. Virol. , vol.64 , pp. 2632-2641
    • Maass, D.R.1    Atkinson, P.H.2
  • 30
    • 51349140305 scopus 로고    scopus 로고
    • H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses
    • Mahmood, K., et al. 2008. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 26:5393-5399.
    • (2008) Vaccine , vol.26 , pp. 5393-5399
    • Mahmood, K.1
  • 31
    • 79551518897 scopus 로고    scopus 로고
    • Characteristics of the earliest cross-neutralizing antibody response to HIV-1
    • Mikell, I., et al. 2011. Characteristics of the earliest cross-neutralizing antibody response to HIV-1. PLoS Pathog. 7:e1001251.
    • (2011) PLoS Pathog , vol.7
    • Mikell, I.1
  • 32
    • 0042825878 scopus 로고    scopus 로고
    • Virus-like particles as immunogens
    • Noad, R., and P. Roy. 2003. Virus-like particles as immunogens. Trends Microbiol. 11:438-444.
    • (2003) Trends Microbiol , vol.11 , pp. 438-444
    • Noad, R.1    Roy, P.2
  • 33
    • 64549129973 scopus 로고    scopus 로고
    • Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure
    • Noah, D. L., H. Hill, D. Hines, E. L. White, and M. C. Wolff. 2009. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin. Vaccine Immunol. 16:558-566.
    • (2009) Clin. Vaccine Immunol. , vol.16 , pp. 558-566
    • Noah, D.L.1    Hill, H.2    Hines, D.3    White, E.L.4    Wolff, M.C.5
  • 34
    • 77954982131 scopus 로고    scopus 로고
    • Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternaryspecific antibodies that effectively neutralize HIV-1
    • Pancera, M., et al. 2010. Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternaryspecific antibodies that effectively neutralize HIV-1. J. Virol. 84:8098-8110.
    • (2010) J. Virol. , vol.84 , pp. 8098-8110
    • Pancera, M.1
  • 35
    • 0018421350 scopus 로고
    • Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D-N-acetylneuraminate) substrate
    • Potier, M., L. Mameli, M. Belisle, L. Dallaire, and S. B. Melancon. 1979. Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferylalpha-D-N-acetylneuraminate) substrate. Anal. Biochem. 94:287-296.
    • (1979) Anal. Biochem. , vol.94 , pp. 287-296
    • Potier, M.1    Mameli, L.2    Belisle, M.3    Dallaire, L.4    Melancon, S.B.5
  • 36
    • 77954217881 scopus 로고    scopus 로고
    • Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus
    • Pushko, P., et al. 2010. Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus. Vaccine 28:4771-4776.
    • (2010) Vaccine , vol.28 , pp. 4771-4776
    • Pushko, P.1
  • 37
    • 27944456097 scopus 로고    scopus 로고
    • Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice
    • Pushko, P., et al. 2005. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23:5751-5759.
    • (2005) Vaccine , vol.23 , pp. 5751-5759
    • Pushko, P.1
  • 39
    • 63849131879 scopus 로고    scopus 로고
    • Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    • Scheid, J. F., et al. 2009. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 458:636-640.
    • (2009) Nature , vol.458 , pp. 636-640
    • Scheid, J.F.1
  • 40
    • 34249669303 scopus 로고    scopus 로고
    • Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza
    • Simmons, C. P., et al. 2007. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 4:e178.
    • (2007) PLoS Med , vol.4
    • Simmons, C.P.1
  • 41
    • 41849090140 scopus 로고    scopus 로고
    • Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats
    • Straight, T. M., M. G. Ottolini, G. A. Prince, and M. C. Eichelberger. 2008. Antibody contributes to heterosubtypic protection against influenza A-induced tachypnea in cotton rats. Virol. J. 5:44.
    • (2008) Virol. J. , vol.5 , pp. 44
    • Straight, T.M.1    Ottolini, M.G.2    Prince, G.A.3    Eichelberger, M.C.4
  • 42
    • 0029822596 scopus 로고    scopus 로고
    • Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults
    • Treanor, J. J., et al. 1996. Evaluation of a recombinant hemagglutinin expressed in insect cells as an influenza vaccine in young and elderly adults. J. Infect. Dis. 173:1467-1470.
    • (1996) J. Infect. Dis. , vol.173 , pp. 1467-1470
    • Treanor, J.J.1
  • 43
    • 33645399959 scopus 로고    scopus 로고
    • Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
    • Treanor, J. J., J. D. Campbell, K. M. Zangwill, T. Rowe, and M. Wolff. 2006. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354:1343-1351.
    • (2006) N. Engl. J. Med. , vol.354 , pp. 1343-1351
    • Treanor, J.J.1    Campbell, J.D.2    Zangwill, K.M.3    Rowe, T.4    Wolff, M.5
  • 44
    • 33646067475 scopus 로고    scopus 로고
    • Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults
    • Treanor, J. J., et al. 2006. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J. Infect. Dis. 193:1223-1228.
    • (2006) J. Infect. Dis. , vol.193 , pp. 1223-1228
    • Treanor, J.J.1
  • 45
    • 0035825607 scopus 로고    scopus 로고
    • Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans
    • Treanor, J. J., et al. 2001. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 19:1732-1737.
    • (2001) Vaccine , vol.19 , pp. 1732-1737
    • Treanor, J.J.1
  • 46
    • 0026781840 scopus 로고
    • Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex
    • Tulip, W. R., J. N. Varghese, W. G. Laver, R. G. Webster, and P. M. Colman. 1992. Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J. Mol. Biol. 227:122-148.
    • (1992) J. Mol. Biol. , vol.227 , pp. 122-148
    • Tulip, W.R.1    Varghese, J.N.2    Laver, W.G.3    Webster, R.G.4    Colman, P.M.5
  • 47
    • 0026668006 scopus 로고
    • Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface
    • Tulip, W. R., J. N. Varghese, R. G. Webster, W. G. Laver, and P. M. Colman. 1992. Crystal structures of two mutant neuraminidase-antibody complexes with amino acid substitutions in the interface. J. Mol. Biol. 227:149-159.
    • (1992) J. Mol. Biol. , vol.227 , pp. 149-159
    • Tulip, W.R.1    Varghese, J.N.2    Webster, R.G.3    Laver, W.G.4    Colman, P.M.5
  • 48
    • 70349887757 scopus 로고    scopus 로고
    • Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    • Walker, L. M., et al. 2009. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326:285-289.
    • (2009) Science , vol.326 , pp. 285-289
    • Walker, L.M.1
  • 49
    • 32844456405 scopus 로고    scopus 로고
    • Expression and purification of an influenza hemagglutinin- one step closer to a recombinant protein-based influenza vaccine
    • Wang, K., et al. 2006. Expression and purification of an influenza hemagglutinin- one step closer to a recombinant protein-based influenza vaccine. Vaccine 24:2176-2185.
    • (2006) Vaccine , vol.24 , pp. 2176-2185
    • Wang, K.1
  • 50
    • 45749084541 scopus 로고    scopus 로고
    • Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus
    • Wei, C. J., et al. 2008. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82:6200-6208.
    • (2008) J. Virol. , vol.82 , pp. 6200-6208
    • Wei, C.J.1
  • 51
    • 77958572922 scopus 로고    scopus 로고
    • Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin
    • Weldon, W. C., et al. 2010. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. PLoS One 5:e12466.
    • (2010) PLoS One , vol.5
    • Weldon, W.C.1
  • 52
    • 78651488739 scopus 로고    scopus 로고
    • Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection
    • Wrammert, J., et al. 2011. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208:181-193.
    • (2011) J. Exp. Med. , vol.208 , pp. 181-193
    • Wrammert, J.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.